Home The Wall Street Journal: Alexion to buy Synageva in $8.4 billion biotech deal
 

Keywords :   


The Wall Street Journal: Alexion to buy Synageva in $8.4 billion biotech deal

2015-05-06 13:59:13| Biotech - Topix.net

Alexion Pharmaceuticals Inc. has agreed to buy Synageva BioPharma Corp. in a cash-and-stock deal valued at $8.4 billion, a move that will strengthen Alexion's pipeline of rare-disease treatments. shareholder will receive $115 in cash and 0.6581 Alexion share, for a total consideration of about $225.92 a share based on Alexion's After the deal, Alexion will have eight treatments in clinical trials, including Synageva's experimental enzyme-replacement therapy for patients with mucopolysaccharidosis IIIB, a rare metabolic disease.

Tags: buy street journal deal

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
06.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Forecast Discussion Number 9
05.11Tropical Storm Rafael Wind Speed Probabilities Number 9
05.11Tropical Storm Rafael Public Advisory Number 9
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Forecast Advisory Number 9
05.11Delayed implementation of EID eartag rule requested
More »